Aligos Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Aligos Therapeutics has a total shareholder equity of $67.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $108.8M and $41.6M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$94.54m |
| Eşitlik | US$67.23m |
| Toplam yükümlülükler | US$41.58m |
| Toplam varlıklar | US$108.81m |
Son finansal sağlık güncellemeleri
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Jul 16
Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Recent updates
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry
Jul 31Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Jul 16Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues
May 24Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ALGS's short term assets ($99.6M) exceed its short term liabilities ($23.6M).
Uzun Vadeli Yükümlülükler: ALGS's short term assets ($99.6M) exceed its long term liabilities ($18.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ALGS is debt free.
Borcun Azaltılması: ALGS had no debt 5 years ago.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: ALGS has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: ALGS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.5% each year